AICAR \u00e9s la primera mol\u00e8cula terap\u00e8utica contra el c\u00e0ncer patentada per un centre p\u00fablic espanyol que ha arribat a la fase d\u2019assaig cl\u00ednic. El f\u00e0rmac va ser desenvolupat l\u2019any 2003 per investigadors de l\u2019actual grup d\u2019Apoptosi i c\u00e0ncer de l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) i del Departament de Ci\u00e8ncies Fisiol\u00f2giques II de la Universitat de Barcelona (UB), liderat per Joan Gil. L\u2019any 2004, els drets de desenvolupament i explotaci\u00f3 del producte van ser adquirits per l\u2019empresa Advancell, que el produeix amb el nom comercial d\u2019Acadra\u2122.<\/p>\n
El f\u00e0rmac actua activant mecanismes de mort programada (apoptosi) en les c\u00e8l\u00b7lules tumorals de la leuc\u00e8mia limfoc\u00edtica cr\u00f2nica i en altres c\u00e0ncers de c\u00e8l\u00b7lules B com el limfoma de c\u00e8l\u00b7lules de mantell i el limfoma espl\u00e8nic de la zona marginal.<\/p>\n
L\u2019avantatge del medicament \u00e9s que \u00e9s capa\u00e7 d\u2019actuar contra les c\u00e8l\u00b7lules malignes sense atacar les sanes. Els f\u00e0rmacs existents actualment eliminen les c\u00e8l\u00b7lules T sanes (que formen part del sistema immunol\u00f2gic que defensa l\u2019organisme de les infeccions), juntament amb les tumorals, fet que immunodeprimeix els pacients.<\/p>\n
Fins ara, l\u2019\u00fanica diana molecular coneguda d\u2019AICAR era la prote\u00efna quinasa activada per<\/p>\n
AMP (AMPK). Ara, l\u2019estudi publicat a Blood, coordinat per Joan Gil i del qual s\u00f3n primers coautors els investigadors de l\u2019IDIBELL i la UB Antonio F. Santidri\u00e1n i Diana M Gonz\u00e1lez-Giron\u00e8s, ha demostrat que AICAR indueix apoptosi en els limf\u00f2cits B mitjan\u00e7ant un mecanisme independent d\u2019AMPK. L\u2019estudi demostra com AICAR indueix apoptosi en c\u00e8l\u00b7lules amb mutacions en el gen supressor tumoral p53.<\/p>\n
Segons el coordinador de la investigaci\u00f3, Joan Gil, \u201caix\u00f2 significa que AICAR podria ser una alternativa terap\u00e8utica interessant per als pacients de leuc\u00e8mia limfoc\u00edtica cr\u00f2nica amb la funci\u00f3 de p53 alterada i resistents a la quimioter\u00e0pia convencional\u201d.<\/p>\n
AICAR ha superat estudis precl\u00ednics, que van avaluar la toxicitat i la farmacodin\u00e0mica del f\u00e0rmac. L\u2019any 2007 es va aprovar un assaig cl\u00ednic en malalts de leuc\u00e8mia limfoc\u00edtica cr\u00f2nica, que est\u00e0 actualment en marxa, i sobre el qual es presentaran els primers resultats properament.<\/p>\n
Refer\u00e8ncia de l’article<\/strong> <\/p>\n <\/strong> Santidri\u00e1n AF*<\/strong>, Gonz\u00e1lez-Giron\u00e8s DM*<\/strong>, Iglesias-Serret D*<\/strong>, Coll-Mulet L*<\/strong>, Cosialls AM*<\/strong>, de Frias M*<\/strong>, Camp\u00e0s C*<\/strong>, Gonz\u00e1lez-Barca E*<\/strong>, Alonso E*<\/strong>, Labi V, Viollet B, Benito A, Pons G<\/strong>*, Villunger A, Gil J*<\/strong>. AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells. Blood, 2010 Oct 21;116(16).<\/p>\n","protected":false},"excerpt":{"rendered":" Publicat a la revista Blood Refer\u00e8ncia de l’article Santidri\u00e1n AF* Gonz\u00e1lez-Giron\u00e8s DM* Iglesias-Serret D* Coll-Mulet L* Cosialls AM* de Frias M* Camp\u00e0s C* Gonz\u00e1lez-Barca E* Alonso E* Pons G Gil J*<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[1,448],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-08 21:57:54","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/9712"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=9712"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/9712\/revisions"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=9712"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=9712"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=9712"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}